Epidemiologic evidence of an inverse association of plasma high-density lipoprotein cholesterol (HDL-C) levels with atherosclerotic cardiovascular disease (ASCVD) risk has not translated into positive outcomes in large-scale randomized controlled trials of interventions that raise HDL-C levels.1 Lack of a plausible causal link between HDL-C and ASCVD from Mendelian randomization studies has led to a paradigm shift toward determining whether improving high-density lipoprotein (HDL) function...
